| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Dept of Medicine, Pulmonary Division, University of Alberta, and 2 Institute of Health Economics, Edmonton, Canada
CORRESPONDENCE: D.D. Sin, 2E4.29 Walter C. Mackenzie Centre, University of Alberta, Edmonton, AB T6G 2B7, Canada. Fax: 1 7804076384. E-mail: don.sin@ualberta.ca
Keywords: chronic obstructive pulmonary disease, doses, inhaled corticosteroids, mortality
Received: May 16, 2002
Accepted September 9, 2002
D.D. Sin is supported by a New Investigator Award from the Canadian Institutes of Health Research, Ottawa, Canada, and a Population Health Investigator Award from the Alberta Heritage Foundation for Medical Research, Edmonton, Canada.
 |
Abstract |
|---|
 TOP Abstract MethodsResultsDiscussionReferences |
|---|
Hospital discharge data were used to identify all patients aged 
65 yrs recently hospitalised due to COPD in Alberta, Canada (n=6,740). The relative risk (RR) for all-cause mortality was compared across different dose categories of inhaled corticosteroids (none and low, medium and high doses) following hospital discharge.
Inhaled corticosteroid therapy after discharge was associated with a 25% relative reduction in risk for all-cause mortality (RR 0.75, 95% confidence interval (CI) 0.68–0.82). Patients on medium- or high-dose therapy showed lower risks for mortality than those on low doses (RR 0.77, 95% CI 0.69–0.86 for low dose; RR 0.48, 95% CI 0.37–0.63 for medium dose; and RR 0.55, 95% CI 0.44–0.69 for high dose).
Use of inhaled corticosteroids following hospital discharge for chronic obstructive pulmonary disease was associated with a significant reduction in the overall mortality rate. Low- was inferior to medium- or high-dose therapy in protecting against mortality in chronic obstructive pulmonary disease.
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world and the only major cause of mortality whose incidence is rising 1. Best estimates suggest that, by the year 2020, COPD will be the fifth leading cause of disability (currently twelfth) 2 and the third leading cause of mortality (currently fourth) if current trends continue 3. Ironically, COPD is the most underfunded disease in relation to its burden of illness on society 4
Although some progress has been made in the diagnosis and treatment of COPD during the 1990s, there is a scarcity of therapies that can effectively ameliorate the inevitable decline in lung function or health status of patients suffering from this disorder 5. Since chronic airway inflammation is a prominent feature of COPD 6, some have suggested that inhaled corticosteroids may improve the health outcomes of COPD patients 7. Although data to date have been mixed, the totality of evidence suggests that they reduce the number of clinical exacerbations 8 and retard the decline in health status of COPD patients 9 without significantly modifying the rate of decline in forced expiratory volume in one second (FEV1) 9–13.
These promising results are counterbalanced by recent data linking inhaled corticosteroids to a variety of complications including oral thrush 8, dysphonia 8, bone demineralization 11, 14, cataract formation 15, 16 and glaucoma 17, which generally occur in a dose-dependent fashion. Thus, from a safety perspective, low-dose therapy would be desirable. It remains unclear, however, whether low-dose therapy (<500 µg·day–1 beclomethasone equivalent) offers similar clinical advantages to medium- or high-dose therapy, as there is a scarcity of published data comparing the effects of different dosing levels of these medications on important clinical end-points such as mortality.
Using a large population cohort of patients with moderate-to-severe COPD (previously hospitalised patients) in the province of Alberta, Canada, the dose/response relationship of inhaled corticosteroids and mortality rates in COPD was investigated.
|
Methods |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
65 yrs, who had experienced at least one hospitalisation for COPD as the most responsible diagnosis between April 1, 1994 and March 31, 1998, were included. International Classification of Diseases ninth revision (ICD-9) codes 490.x, 491.x, 492.x and 496.x were used to identify these patients 18. All patients with an admitting diagnosis of asthma (ICD-9 code 493.x) were excluded. Patients who died during the index hospitalisation were also excluded. All hospital visits occurring after the first hospital visit were censored for each study patient in order to avoid double counting.
Drug data
The CIHI database was merged with the Alberta Blue Cross (Edmonton, Canada) database in order to obtain information on medications dispensed for the study cohort. This was possible because all Alberta residents aged 65 yrs receive government subsidies for prescription medications. All claims in this database have a unique identification number for the medication, as well as the quantity and date dispensed. For each study patient, use of all pulmonary medications (short-acting ß2-agonists, ipratropium bromide, inhaled and oral corticosteroids and oral theophyllines), including those prescribed at the time of discharge, was determined for the study period. Data concerning medications received before the patient's index hospital visit were censored.
Study design
The study patients were followed for 3 yrs following discharge from the initial hospitalisation for COPD or until the date of their death, if earlier. Mortality data were obtained from Alberta Vital Statistics (Edmonton, Canada), a government agency that keeps an updated electronic file of all deceased persons in Alberta and includes dates of death. In order to determine the "primary" causes of deaths during the follow-up period for the cohort, discharge abstracts of hospitalisations leading to death were obtained from the CIHI database. All deceased persons with ICD-9 codes 460.x–519.x in the primary diagnostic field were considered to have died from a pulmonary-specific cause of mortality.
Since Alberta Blue Cross provides data on the quantity of medications dispensed rather than the daily dose, the mean daily dose of inhaled corticosteroids was imputed by determining the total dose of medications dispensed for each patient for the first two prescriptions and dividing the total dose of the first dispensation by follow-up time (in days) between these two doses. The calculated mean dose was rounded to a clinically plausible dose 19. If, for example, a patient was prescribed beclomethasone at a dose of 200 puffs (250 µg·puff–1) and the elapsed time between the first and second prescription was 100 days, the calculated mean daily dose would be 500 µg.
To allow cross-comparisons between different inhaled corticosteroid preparations, all formulations were converted into beclomethasone dipropionate equivalents based on equivalency calculations suggested by the Canadian Asthma Consensus Report 20. The daily dose was then divided into five mutually exclusive categories: not dispensed and low (
500 µg·day–1 beclomethasone or equivalent), medium (501–1,000 µg·day–1), high (>1,000 µg·day–1) and indeterminate dose. The last category contained patients who received only one dispensation of inhaled corticosteroids during the follow-up period. Although the mean daily dose could not be calculated for these individuals, they most probably received a mean daily dose lower than that received in the low-dose category.
Other factors
The effect of comorbid conditions was determined using the CIHI database. A modified Charlson comorbidity score was calculated for each individual patient using the ICD-9 codes in the 15 secondary diagnosis fields. In order to derive this score, the following comorbid conditions were taken into account: congestive heart failure (ICD-9 code 428.x), ischaemic heart disease (ICD-9 codes 410.x and 412.x), peripheral vascular disease (ICD-9 codes 443.9, 441.x, 785.4 and V43.4), cerebrovascular accidents (ICD-9 codes 430.x–438.x), dementia (ICD-9 code 290.x), rheumatological diseases (ICD-9 codes 710.0, 710.1, 710.4, 714.0–714.2, 714.81 and 725.x), peptic ulcer disease (ICD-9 codes 531.x–534.9), diabetes (ICD-9 codes 250.0–250.7), malignancy (ICD-9 codes 140.x–172.9, 174.x–195.8, 196.x–199.1 and 200.x–208.9) and renal (ICD-9 codes 582.x, 583.x, 585.x, 586.x and 588.x) and liver diseases (ICD-9 codes 571.x and 572.x) 21. A Charlson comorbidity score of zero denotes the absence of any comorbid conditions; higher numbers indicate an increasing burden of comorbidity.
Statistical analysis
The mean and sd of continuous variables were compared using analysis of variance adjusted for multiple comparisons through Tukey's test. Ordinal and binary variables were compared using a Chi-squared test (with an appropriate number of degrees of freedom).
The mortality rates of patients who received and did not receive inhaled corticosteroids during the follow-up period were compared using the Cox proportional hazards model. In this model, age, sex, Charlson comorbidity score, admission to an intensive care unit (ICU) during the initial hospital stay (yes or no variable) and filling in prescriptions for various pulmonary medications, including short-acting ß2-agonists, ipratropium bromide, oral corticosteroids and oral theophyllines, were controlled for. Age was divided into three ranges: 65–74, 75–84 and 85 yrs. Similarly, the Charlson comorbidity score was categorised into three groups: 0, 1–2 and 3. In order to increase the validity of the model, a group-corrected prognosis method was used for constructing the adjusted survival curves 22. A similar Cox proportional model was used to compare adjusted survival (using a group-corrected prognosis method) among those on no and low-, medium-, indeterminate- and high-dose therapy.
A series of secondary analyses were conducted in order to determine the robustness of the findings. It was reasoned that real differences in the effects of different doses of inhaled corticosteroid therapy should be most obvious when compared in a relatively young and healthy subgroup 23. Therefore, patients aged 65–74 yrs with no documented comorbid conditions were identified and a similar survival analysis was performed in this group of patients using a Cox proportional hazards model. Confounding by age and comorbid conditions should be minimal in this group of patients 23.
|
Results |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
65 yrs who had experienced at least one hospital visit due to their COPD during the study period (n=6,740) were identified. The mean age of the study population was 76.2±7.2 yrs. Of these patients: 3,661 (54.3%) were male; 3,744 (55.6%) had no comorbid conditions; 2,736 (40.6%) had a Charlson comorbidity score of 1 or 2; 260 (3.9%) had a Charlson comorbidity score of 3; and 356 (5.3%) were admitted to an ICU during the initial hospitalisation. The mean duration of follow-up was 31.7±19.3 months. Of the patients: 4,725 (70.1%) received at least one dispensation of a short-acting ß2-adrenergic medication; 3,751 (55.6%) received ipratropium bromide; 3,144 (46.6%) received oral corticosteroids; and 1,950 (28.9%) received oral theophyllines (table 1
).
|
Survival
During the follow-up period, there were 2,404 (35.7%) deaths in the cohort. On crude analysis, therapy with inhaled corticosteroids was associated with 39% fewer deaths than in those not on these medications (relative risk (RR) 0.61, 95% confidence interval (CI) 0.56–0.66). After adjustments for age, sex, comorbid conditions, ICU stay and use of other pulmonary medications, a 25% reduction in the overall mortality rate was observed in those who received inhaled corticosteroids compared to those who did not (RR 0.75, 95% CI 0.68–0.82) (fig. 1).
|
). Patients on indeterminate doses did not experience any significant decline in all-cause mortality rate (RR 0.88, 95% CI 0.76–1.03; p=0.108).
|
, and include advanced age, male sex and a Charlson comorbidity score of 1. Use of oral theophyllines and oral corticosteroids was not associated with increased mortality. However, there was a slight increase in risk among those who used ß2-adrenergics or ipratropium bromide.
|
). Survival benefits of inhaled corticosteroids were observed across different age groups, sexes, and comorbidity and medication statuses.
|
Since survivor treatment selection bias 24 was a potential concern in the analysis, sensitivity analyses were performed including only certain subgroups. For instance, a subgroup analysis was performed excluding all patients who had a follow-up of 90 days and, therefore, a lower probability of having received inhaled steroids than the rest of the cohort. In this analysis, inhaled corticosteroids were associated with a 43% lower risk of mortality (RR 0.57, 95% CI 0.51–0.63). Using cut-offs of 6, 9 and 12 months made little difference to the overall findings (RR 0.57 for 6 months, 0.58 for 9 months and 0.58 for 12 months), suggesting that survivor treatment selection bias was not a significant concern in the analysis.
The impact of inhaled corticosteroids on pulmonary-specific causes of mortality was evaluated. It was found that inhaled corticosteroid therapy was associated with a 30% risk reduction (RR 0.70, 95% CI 0.53–0.93) in pulmonary-specific mortality rate.
|
Discussion |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
These findings are supported by the results of a recently published systematic review of all randomised controlled trials, demonstrating the beneficial effects of inhaled corticosteroids on clinical outcomes such as exacerbation rate 8. Interestingly, these benefits occurred in the absence of any appreciable effect on rate of decline in FEV1 9–13. The mechanisms underlying these observations remain largely unknown. Although corticosteroids are less effective at neutralising COPD-related airway inflammation than that occurring in asthma, several 25–27, but not all 28, 29, studies have demonstrated that therapy with moderate-to-high doses of inhaled corticosteroids for several weeks can significantly attenuate some of the components of airway inflammation in COPD. Inhaled corticosteroids may also attenuate airway hyperresponsiveness 11, a known risk factor for morbidity and mortality in COPD 30.
The present findings are also similar to those of a previous report on patients in Ontario, Canada 18. In that study, it was demonstrated that inhaled corticosteroids reduced the risk of hospitalisation and all-cause mortality over a 12-month period. However, this study did not evaluate the relationship between mortality and dose of inhaled corticosteroids. The present study extends the earlier findings by demonstrating that the survival benefits of inhaled corticosteroids are maintained for 3 yrs. As in the present study, in their meta-analysis, van Grunsven et al. 31 showed that high-dose therapy (defined in their study as 1,500 µg·day–1 beclomethasone or 1,600 µg·day–1 budesonide) improved flow/volume measurements in lung function tests over time, whereas low doses and placebos did not. In addition, there were no significant differences in the rate of decline in flow/volume measurements between low- and medium-dose therapy. Since important clinical changes can occur in the absence of a discernible effect on flow/volume 9, van Grunsven et al. 31 might have missed subtle but important differences in clinical outcome between those on low- and medium-dose therapy. Nevertheless, this systematic review is consistent with the present observation that low-dose therapy is less efficacious than higher doses of inhaled corticosteroids in COPD.
In the present study, a consistent relationship between oral corticosteroid therapy and mortality was not observed. The study of Strom 32 showed that oral corticosteroids were associated with increased risk of hospitalisation in females but not in males. In the study of Schols et al. 33, oral corticosteroid therapy in moderate-to-high doses was associated with increased mortality risk but only in the absence of concomitant inhaled steroid therapy. When combined with inhaled corticosteroids, oral steroid therapy, even at high doses, did not significantly increase the mortality rate 33. Although it is evident that oral corticosteroids are fraught with many serious adverse effects, they may also produce some clinical benefits 34, particularly in the short term. Thus, the benefit/risk ratio of these medications remains uncertain.
Several limitations of the present study should be addressed. First, no clinical outcomes other than survival were measured. Although mortality is a critically important outcome for assessing the effectiveness of medications, it is by no means the only end-point germane for clinical practice 35. Health-related quality of life and other morbidity measurements matter to patients and their physicians. The present authors' databases did not contain such information, an important limitation of the present study. Secondly, because baseline lung function data were not available, it was not possible to be certain whether patients receiving low-, medium- or high-dose therapy had similar disease severity. In clinical practice, clinicians generally treat the mildest cases with the lowest doses and reserve high doses for those with either refractory disease or the greatest disease burden. The finding that low-dose therapy is inferior to higher doses of inhaled corticosteroids for reducing mortality risks in COPD is likely to be unchanged by disease severity data. Moreover, a variety of sensitivity analyses were performed and similar results found across all strata, suggesting that the findings are robust and consistent and unlikely to have been confounded by (measured and unmeasured) external factors. Thirdly, if patients who were dispensed inhaled corticosteroids were more likely to have had clinical features of asthma than those who did not receive these medications, the beneficial effect of inhaled steroids would have been overestimated. In order to minimise this bias, all patients who had a primary diagnosis of asthma were excluded from the study. Moreover, the analysis was restricted to the elderly who had required at least one hospitalisation for their disease. Since such patients are very likely to have respiratory failure on the basis of COPD and not asthma, diagnostic bias is unlikely to explain away the present findings 36.
An observational study such as the present one is not intended to replace data from randomised controlled trials, since observational studies are much more susceptible to confounding and bias 37. Accordingly, the present findings should be interpreted cautiously and conservatively. Nevertheless, these data provide a solid rationale for the systematic evaluation of the effects of inhaled corticosteroids (in varying doses) on hard clinical end-points such as mortality.
In summary, the present study shows a protective benefit of inhaled corticosteroids in mortality that extends to 3 yrs. Moreover, medium- and high-dose therapy are related to improved survival compared to low or indeterminate doses. These data suggest an important role of inhaled corticosteroid therapy in improving clinical outcomes in these high-risk chronic obstructive pulmonary disease patients. They also suggest that, when using inhaled corticosteroids for chronic obstructive pulmonary disease, clinicians should consider using 500 µg·day–1 beclomethasone (or equivalent) to achieve maximal survival benefits. These results are dissimilar to those in asthma, where low-dose therapy appears to achieve similar clinical outcomes to medium- or high-dose therapy 38. Clinical trials are needed to confirm these early findings.
|
Footnotes |
|---|
|
References |
|---|
|
TOPAbstractMethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Suissa, R. McGhan, D. Niewoehner, and B. Make Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, October 1, 2007; 4(7): 535 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Macie, K. Wooldrage, J. Manfreda, and N. R. Anthonisen Inhaled Corticosteroids and Mortality in COPD. Chest, September 1, 2006; 130(3): 640 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. D'Souza, M. J. Smith, L. A. Miller, and J. Kavookjian An Appraisal of Pharmacoeconomic Evidence of Maintenance Therapy for COPD Chest, June 1, 2006; 129(6): 1693 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gartlehner, R. A. Hansen, S. S. Carson, and K. N. Lohr Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes Ann. Fam. Med, May 1, 2006; 4(3): 253 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Kiri, N. B. Pride, J. B. Soriano, and J. Vestbo Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Results from Two Observational Designs Free of Immortal Time Bias Am. J. Respir. Crit. Care Med., August 15, 2005; 172(4): 460 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. P. Man and D. D. Sin Effects of Corticosteroids on Systemic Inflammation in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 78 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Buhl and S. G. Farmer Future Directions in the Pharmacologic Therapy of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, April 1, 2005; 2(1): 83 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Mapel Treatment Implications on Morbidity and Mortality in COPD Chest, August 1, 2004; 126(2_suppl_1): 150S - 158S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suissa Inhaled steroids and mortality in COPD: bias from unaccounted immortal time Eur. Respir. J., March 1, 2004; 23(3): 391 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gotfried Macrolides for the Treatment of Chronic Sinusitis, Asthma, and COPD Chest, February 1, 2004; 125(2_suppl): 52S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. S. Fan, C. L. Bryson, J. R. Curtis, S. D. Fihn, P.-O. Bridevaux, M. B. McDonell, and D. H. Au Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease and Risk of Death and Hospitalization: Time-dependent Analysis Am. J. Respir. Crit. Care Med., December 15, 2003; 168(12): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P S Burge and S A Lewis So inhaled steroids slow the rate of decline of FEV1 in patients with COPD after all? Thorax, November 1, 2003; 58(11): 911 - 913. [Full Text] [PDF]
|
|
|
|
|
|
The pharmacoepidemiology of COPD: Recent advances and methodological discussion Eur. Respir. J., September 1, 2003; 22(43_suppl): 1S - 44s. [Full Text] [PDF]
|
|
|
|
|
|
D. D. Sin, S. F. P. Man, J. V. Tu, N. B. Pride, J. Vestbo, J. B. Soriano, and V. A. Kiri Inhaled glucocorticoids in COPD: Immortal time bias Am. J. Respir. Crit. Care Med., July 1, 2003; 168(1): 126 - 127. [Full Text] [PDF]
|
|
|
|
|
|
M R Partridge Patients with COPD: do we fail them from beginning to end? Thorax, May 1, 2003; 58(5): 373 - 375. [Full Text]
|
|
|
|
|
|
J. Bourbeau Inhaled corticosteroids and survival in chronic obstructive pulmonary disease Eur. Respir. J., February 1, 2003; 21(2): 202 - 203. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) inhaled corticosteroids following their index hospitalisation. The curves were generated using the group-corrected prognosis method. p=0.001.